Top 25 global pharmaceutical companies by market cap Q2 2018, researched by GlobalData

The performance highlights of the Top 25 publicly traded global pharmaceutical companies by Market Cap (Mcap) for the quarter ended June 30, 2018 (Q2) ), compared to the quarter ended March 31, 2018 (Q1), have been analyzed in the latest research from GlobalData, a leading data and analytics company. The completed analysis revealed a number of interesting insights.

IMAGE FOR PUBLICATION: Please click here for chart: Top 25 global pharma companies market cap day vs day comparison Q1 2018 v Q2 2018

The top 25 pharmaceutical companies collective Mcap reached around $2.7tn, growing marginally at 1.1% in Q2 2018 with leading companies Merck US, Bayer, GSK, Eli Lilly, CSL and Shire achieving double digit Mcap growth during the same period.

J&J maintained its No.1 position in the Top 25 with Chinese pharmaceutical company, Jiangsu Hengrui Medicine, entering the list during the period.

Six of the top 25 companies experienced positive Mcap growth in Q2 2018, with CSL, Shire and Bayer achieving double digit growth rates of 24%, 20% and 16%, respectively.

The Mcap of BMS and Celgene declined over 10% in Q2 2018. Institutional investors in BMS traded a substantial amount of shares in the period which is thought to have impacted their Mcap performance while setbacks in some key pipeline drugs affected Celgene’s Mcap value.

There were plenty of new developments and market activity during Q2 2018, reflecting a growing trend among the big pharma companies to focus on their core business areas. BMS announced its intention to sell its French consumer health business, P&G acquired Merck KGaA’s vitamin brands; GSK bought the consumer healthcare joint venture from Novartis for $13bn and Pfizer announced plans to divest its European generic-drug business.

IMAGE FOR PUBLICATION: Please click here for chart: Top 25 global pharma companies market cap day vs day comparison Q1 2018 v Q2 2018

In geographical terms, North America contributed an aggregate Mcap of $1.5tn, with 13 companies from this region featuring in the top 25 list. The Mcap of European and Asia-Pacific (APAC) pharmaceutical companies grew 3.2% and 16.5% respectively during the period.


For more information

To gain access to our latest press releases: GlobalData Media Centre

Analysts available for comment. Please contact the GlobalData Press Office:

EMEA & Americas: +44 (0)207 832 4399
Asia-Pacific: +91 40 6616 6809


For expert analysis on developments in your industry, please connect with us on: | LinkedIn | Twitter

Notes to Editors

The source data for this analysis has been taken from global stock exchange latest share price and market cap valuations together with end of year numbers from the companies own latest annual reports.

About GlobalData

4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors. PR2667

More Media